Harmony Biosciences Holdings, Inc. HRMY Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $589.4M-21.7% | $752.5M+16.3% | $647M+18.5% | $546.05M+11.7% | $489M+7.9% | ||
| $51.52M+126% | $22.84M-10.7% | $25.58M+33.1% | $19.22M+7.1% | $17.96M+26.6% | ||
| $108.22M+11.8% | $96.79M-3.8% | $100.65M+8.2% | $92.98M-12.3% | $105.97M+27.6% | ||
| $5.28M-1.4% | $5.36M-22.2% | $6.88M+12.8% | $6.1M-4.4% | $6.38M-11.3% | ||
| $16.8M+4.9% | $16.01M-31.3% | $23.31M+26.9% | $18.36M+11.5% | $16.47M+20.1% | ||
| $778.82M-14.1% | $907.01M+8.1% | $838.8M+21.3% | $691.35M+7.6% | $642.69M+11.0% | ||
| $83.46M-6.7% | $89.42M-6.3% | $95.38M-5.9% | $101.34M-5.6% | $107.3M-5.3% | ||
| $26.43M+43.9% | $18.37M+89.6% | $9.69M+77.3% | $5.47M-8.0% | $5.94M-19.9% | ||
| $229.56M+114% | $107.13M+1.2% | $105.83M-1.1% | $107.01M+3.6% | $103.25M-5.2% | ||
| $493.01M+35.2% | $364.62M-1.3% | $369.42M-11.3% | $416.65M+0.9% | $412.84M-1.7% | ||
| $1.27B0.0% | $1.27B+5.2% | $1.21B+9.0% | $1.11B+5.0% | $1.06B+5.6% | ||
| $28.6M+61.6% | $17.69M-32.8% | $26.34M-6.9% | $28.3M+62.1% | $17.46M+27.0% | ||
| $6.73M-63.5% | $18.44M+23.5% | $14.94M+27.3% | $11.74M+54.8% | $7.58M-59.6% | ||
| $20M0.0% | $20M0.0% | $20M+6.7% | $18.75M+7.1% | $17.5M+7.7% | ||
| $1.27M+18.1% | $1.07M+30.1% | $825K-2.5% | $846K-26.3% | $1.15M-12.9% | ||
| $217.34M-13.8% | $252.13M+12.9% | $223.4M+24.0% | $180.14M+2.9% | $175.12M0.0% | ||
| $138.81M-3.4% | $143.66M-3.3% | $148.51M-3.2% | $153.35M-3.1% | $158.18M-3.0% | ||
| $5.8M+3.8% | $5.59M+355% | $1.23M-3.9% | $1.28M-28.3% | $1.78M-16.7% | ||
| $5.32M-5.3% | $5.62M+374% | $1.19M-18.1% | $1.45M-15.3% | $1.71M-12.2% | ||
| $144.14M-3.4% | $149.28M-0.3% | $149.69M-3.3% | $154.79M-3.2% | $159.89M-3.1% | ||
| $361.48M-9.9% | $401.41M+7.6% | $373.1M+11.4% | $334.93M0.0% | $335.01M-1.5% | ||
| $1K0.0% | $1K0.0% | $1K0.0% | $1K0.0% | $1K0.0% | ||
| $717.37M+1.2% | $708.97M+1.8% | $696.35M+1.6% | $685.29M+1.9% | $672.5M+2.4% | ||
| $193.39M+20.2% | $160.9M+16.2% | $138.42M+58.1% | $87.55M+83.3% | $47.78M+2,056% | ||
| -$413K-219% | $346K-3.1% | $357K+49.4% | $239K-2.4% | $245K+271% | ||
| $910.35M+4.6% | $870.22M+4.2% | $835.12M+8.0% | $773.08M+7.3% | $720.53M+9.3% | ||
| $1.27B0.0% | $1.27B+5.2% | $1.21B+9.0% | $1.11B+5.0% | $1.06B+5.6% | ||
| $7.6M-43.8% | $13.52M-61.8% | $35.38M+310% | $8.64M+24.9% | $6.92M-14.8% | ||
| $26.43M+43.9% | $18.37M+89.6% | $9.69M+77.3% | $5.47M-8.0% | $5.94M-19.9% | ||
| $153.56M+2.6% | $149.7M-4.7% | $157.08M-21.9% | $201.19M+3.3% | $194.71M+2.3% | ||
| $83.46M-6.7% | $89.42M-6.3% | $95.38M-5.9% | $101.34M-5.6% | $107.3M-5.3% | ||
| $229.56M+114% | $107.13M+1.2% | $105.83M-1.1% | $107.01M+3.6% | $103.25M-5.2% | ||
| $26.43M+43.9% | $18.37M+89.6% | $9.69M+77.3% | $5.47M-8.0% | $5.94M-19.9% | ||
| $51.52M+126% | $22.84M-10.7% | $25.58M+33.1% | $19.22M+7.1% | $17.96M+26.6% | ||
| $26.43M+43.9% | $18.37M+89.6% | $9.69M+77.3% | $5.47M-8.0% | $5.94M-19.9% | ||
| $6.73M-63.5% | $18.44M+23.5% | $14.94M+27.3% | $11.74M+54.8% | $7.58M-59.6% | ||
| $150.11M-21.4% | $191.04M— | —— | —— | —— | ||
| $150.11M-21.4% | $191.04M— | —— | —— | —— | ||
| $6.73M-63.5% | $18.44M+23.5% | $14.94M+27.3% | $11.74M+54.8% | $7.58M-59.6% | ||
| $11.91M+140% | $4.96M+501% | $825K-73.0% | $3.06M-84.6% | $19.88M+250% | ||
| $164.61M-2.7% | $169.25M-0.3% | $169.73M-2.1% | $173.37M-2.3% | $177.46M-2.2% | ||
| $717.37M+1.2% | $708.97M+1.8% | $696.35M+1.6% | $685.29M+1.9% | $672.5M+2.4% | ||
| $1K0.0% | $1K0.0% | $1K0.0% | $1K0.0% | $1K0.0% | ||
| $16.8M+4.9% | $16.01M-31.3% | $23.31M+26.9% | $18.36M+11.5% | $16.47M+20.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Harmony Biosciences Holdings, Inc. cover its short-term obligations?
- Its current ratio is 3.58 — current assets exceed current liabilities.
- Where does Harmony Biosciences Holdings, Inc.'s balance sheet data come from?
- Every line is extracted from Harmony Biosciences Holdings, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.